NCT01281592

A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Aptose Biosciences Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, phase 1 study to determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.

Conditions

• Advanced or Metastatic Solid Tumours

Interventions

Type	Name	Description
DRUG	LOR-253 HCl	LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.

Timeline

• Start date: 2011-01-01
• Primary completion: 2013-07-01
• Completion: 2014-01-01
• First posted: 2011-01-24
• Last updated: 2014-02-25

Locations

2 sites across 1 country: United States